Erythropoiesis-stimulating Agents (ESA) can stimulate EPO production, elevate hemoglobin levels, and ameliorate anemia, representing a primary therapeutic approach for addressing low hemoglobin levels in CKD patients17. The gene discussed is EPO; the disease is anemia.